Ocugen, Inc. (NASDAQ:OCGN) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET

Company Participants

Tiffany Hamilton - Head, Corporate Communications
Shankar Musunuri - Chairman, CEO & Co-Founder
Michael Breininger - Corporate Controller
Arun Upadhyay - CSO, Head R&D
Huma Qamar - CMO

Conference Call Participants

Arthur He - H.C. Wainwright
Robert LeBoyer - Noble Capital Markets
Daniil Gataulin - Chardan

Operator

Good morning, and welcome to Ocugen's First Quarter 2024 Financial Results and Business Update. Please note that this call is being recorded. At this time, all participants' lines are in listen-only mode. Following the speakers' commentary, there will be a question-and-answer session.

I will now turn the call over to Tiffany Hamilton, Ocugen's Head of Corporate Communications. You may begin.

Tiffany Hamilton

Thank you, operator, and good morning, everyone. Joining me on today's call and webcast is Dr. Shankar Musunuri, Ocugen's Chairman, CEO, and Co-Founder, who will provide a business update and an overview of our clinical and operational progress; Michael Breininger, our Corporate Controller, is also on the call to provide a financial update for the quarter ended March 31, 2024; Dr. Arun Upadhyay, Chief Scientific Officer, Head of Research and Development; and Dr. Huma Qamar, Chief Medical Officer will be available to answer questions following the presentation.

This morning, we issued a press release detailing associated business and operational highlights for the first quarter of 2024. We encourage listeners to review the press release, which is available on our website at ocugen.com. This call is being recorded and a replay with the accompanying slide presentation will be available on the Investors section of the Ocugen website for approximately 45 days.

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may in some cases use terms such as predicts, believes, potential, proposed, continue, estimate, anticipate, expect, plans, intends, may, could, might, will, should, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.

Such statements include, but are not limited to statements regarding our clinical development activities and related anticipated timelines. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations.

These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission, the SEC, including the risk factors described in the section entitled, "Risk Factors", and the Annual Report we filed with the SEC. Any forward-looking statements that we make in this presentation speak only as of the date of the presentation. Except as required by law, we assume no obligation to update forward-looking statements contained in this presentation whether as a result of new information, future events or otherwise after the date of this presentation. Finally, Ocugen's quarterly report Form 10-Q covering the first quarter of 2024 has been filed.